^
    Back
    Association details:
    Biomarker:YWHAE-NUTM2A translocation
    Cancer:Endometrial Cancer
    Drug:gemcitabine (DNA synthesis inhibitor) +
    docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Gynecol Oncol
    Title:

    YWHAE-Rearranged High-Grade Endometrial Stromal Sarcoma: Two-Center Case Series and Response to Chemotherapy

    Excerpt:
    Seven patients were identified with YWHAE-rearranged HG-ESS...Median follow-up for the cohort was 27 months (range 6–123)...Combination gemcitabine and docetaxel was also found to be effective as first-line therapy in one patient....
    DOI:
    10.1016/j.ygyno.2017.03.021